University of Pennsylavania/Abramson Cancer Center — Philadelphia, Pennsylvania

University of Pennsylavania/Abramson Cancer Center is a clinical research site located in Philadelphia, Pennsylvania, United States 19104.

Crixeo Clinical Trials Trust Score: 85/100 (GOOD). This profile has not yet been claimed by the site owner.

University of Pennsylavania/Abramson Cancer Center has participated in 1 clinical trials.

Therapeutic areas: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma.

Sponsors: National Cancer Institute (NCI).

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Philadelphia

Browse all research sites in Pennsylvania · View every site in Philadelphia

Sponsor Feasibility Report

Trust Score: 85/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Pennsylavania/Abramson Cancer Center?

University of Pennsylavania/Abramson Cancer Center has a Crixeo Trust Score of 85/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Pennsylavania/Abramson Cancer Center conducted?

University of Pennsylavania/Abramson Cancer Center has 1 clinical trials on record. Their work covers Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma.

Is University of Pennsylavania/Abramson Cancer Center accredited by Crixeo Clinical Trials?

University of Pennsylavania/Abramson Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Pennsylavania/Abramson Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.